Selectivity, ligand deconstruction, and cellular activity analysis of a BPTF bromodomain inhibitor

Steven E. Kirberger, Peter D. Ycas, Jorden A. Johnson, Chen Chen, Michael F. Ciccone, Rinette W.L. Woo, Andrew K. Urick, Huda Zahid, Ke Shi, Hideki Aihara, Sean D. McAllister, Mohammed Kashani-Sabet, Junwei Shi, Alex Dickson, Camila O. Dos Santos, William C.K. Pomerantz

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Bromodomain and PHD finger containing protein transcription factor (BPTF) is an epigenetic protein involved in chromatin remodelling and is a potential anticancer target. The BPTF bromodomain has one reported small molecule inhibitor (AU1, rac-1). Here, advances made on the structure-activity relationship of a BPTF bromodomain ligand are reported using a combination of experimental and molecular dynamics simulations leading to the active enatiomer (S)-1. Additionally, a ligand deconstruction analysis was conducted to characterize important pharmacophores for engaging the BPTF bromodomain. These studies have been enabled by a protein-based fluorine NMR approach, highlighting the versatility of the method for selectivity, ligand deconstruction, and ligand binding. To enable future analysis of biological activity, cell growth analyses in a panel of cancer cell lines were carried out using CRISPR-Cas9 and (S)-1 to identify cell-based model systems that are sensitive to BPTF inhibition.

Original languageEnglish (US)
Pages (from-to)2020-2027
Number of pages8
JournalOrganic and Biomolecular Chemistry
Issue number7
StatePublished - 2019

Bibliographical note

Publisher Copyright:
© The Royal Society of Chemistry 2019.


Dive into the research topics of 'Selectivity, ligand deconstruction, and cellular activity analysis of a BPTF bromodomain inhibitor'. Together they form a unique fingerprint.

Cite this